Japanese Regulators Recommend Wyeth-Pfizer's Torisel And Celgene's Revlimid For Approval
This article was originally published in PharmAsia News
Executive Summary
The Second Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare on May 31 recommended Wyeth-Pfizer's Torisel (temsirolimus) and Celgene's Revlimid (lenalidomide) for approval. The approvals came with post-market surveillance requirements and a restricted distribution system in the case of Revlimid